NEW YORK – Diaceutics announced on Thursday that LGC SeraCare is joining its DXRX platform intended to help develop and commercialize precision medicine diagnostics.
Under the partnership, additional types of test reference materials and technologies will be added to the network, including Seraseq FFPE Tumor Fusion RNA Reference Material v4 and Seraseq FFPE NTRK Fusion RNA Reference Material. The addition of these materials will allow labs "to provide consistently high quality testing using reference material to validate their test system, faster," the companies said in a statement.
"As the post-Covid testing landscape emerges with new complexity, it is now more critical than ever that pharma are collaborating digitally with key stakeholders in the testing supply chain to guarantee diagnostic testing accuracy," Kenneth Bloom, DXRX Network adviser, said in a statement.
Other lab testing solutions companies on the platform include Targos Molecular Pathology, Histocyte Laboratories, and Alva10. External quality assessment organizations are also on the platform.